Archon adds $20 million pot to Nobel Prize endorsement

A new Seattle-based biotech company has the best endorsement imaginable as it emerges from stealth.

Archon Biosciences’ platform, leveraging AI-driven advances in computational protein design, were recognized earlier this month by the awarding of the 2024 Nobel Prize in Chemistry, for its ability to create novel proteins with desired functions.

One of this year’s three laureates, University of Washington (UW) Professor of Biochemistry and Howard Hughes Medical Institute investigator, David Baker, leads the Institute for Protein Design (IPD), where he co-invented the Archon platform, alongside co-founders and former UW Research Faculty and IPD Translational Investigators James Lazarovits and George Ueda.